Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks. I found this company by following Randal J Kirk and his company Intrexon (XON). They have a list of exclusive channel collaborations, OGEN is one of them. I've been adding many of them (ZIOP, SYN, SNGX) to my bio portfolio. I added links to Kirk's background & his company's ECC's. Best of luck to you.
http://en.m.wikipedia.org/wiki/Randal_J._Kirk
http://intrexon.com/Collaborations/Exclusive-Channel-Collaborations
Maybe, I just noticed it & bought in today
Sorry, I misspelled it. Meant to say stocktwits, link below
http://stocktwits.com/symbol/XON?q=Xon
I read that board as well & follow RobCos recommendations. I'm also on stocktwits-m22
Exclusive Licensing Agreement for CAR T Cell, TCR, NK Cell Programs and Associated Technologies for the Development of Non-Viral Adoptive Cellular Therapies
Combined Technologies to Leapfrog Clinical Pipeline of Next Generation Therapies Using Synthetic and Personalized Immunology
GERMANTOWN, Md., BOSTON, and HOUSTON, Jan. 13, 2015 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology and its oncology partner, ZIOPHARM Oncology (NASDAQ: ZIOP), today announced a broad exclusive licensing agreement with The University of Texas MD Anderson Cancer Center, including an exclusive sublicensing agreement through MD Anderson for intellectual property developed at the University of Minnesota for the development of non-viral adoptive cellular cancer immunotherapies.
The licensed technologies arise from the laboratory of Laurence Cooper, M.D., Ph.D., professor of pediatrics at MD Anderson and Perry Hackett, Ph.D., professor within the College of Biological Sciences at Minnesota.  The Cooper and Hackett laboratories have pioneered the design and clinical investigation of novel chimeric antigen receptor (CAR) T cell therapies using non-viral gene integration platforms. MD Anderson has built on this technology to deliver patient-derived T cells, as well as innovative approaches to generating products for universal off-the-shelf applications.  When combined with Intrexon's technology suite and ZIOPHARM's clinically tested RheoSwitch Therapeutic System® interleukin-12 modules, the resulting proprietary methods and technologies may help realize the promise of genetically modified CAR T cells by tightly controlling cell expansion and activation in the body, minimizing off-target effects and toxicity while maximizing therapeutic efficacy.
"Genetically engineering our patients' immune-system T cells to efficiently attack and destroy cancer cells represents one of the most exciting approaches with curative potential in oncology today," MD Anderson President Ron DePinho, M.D., said. "We believe coupling MD Anderson's unique CAR T cell approach with the powerful technologies of ZIOPHARM and Intrexon will allow us to build T cells that hit cancer harder, with greater precision, under tighter control and with potentially fewer side effects for patients. This agreement ranks as one of MD Anderson's most substantial collaborations and will provide significant resources to fuel its mission of Making Cancer History®."
"We are proud to see Perry Hackett's discovery and development work on Sleeping Beauty, a non-viral DNA plasmid-based gene transfer system, in conjunction with Dr. Cooper's expertise in immunotherapies, provide this breakthrough in oncology" said Brian Hermann, Vice President of Research at the University of Minnesota.
Employing novel cell engineering techniques and multigenic gene programs, the collaboration will implement next-generation non-viral adoptive cellular therapies based on designer cytokines and CARs under control of RheoSwitch® technology targeting both hematologic and solid tumor malignancies. The synergy between the platforms will be leveraged to accelerate a promising synthetic immunology pipeline, with up to five CARs expected to enter the clinic in 2015 and off-the-shelf programs initiating in 2016.
"It is a shared vision to maximize the speed and breadth of multigenic innovation for patients through the use of nimble, non-viral DNA cell manufacturing strategies that can further overcome viral packaging constraints and economic limitations," stated Gregory Frost, Ph.D., Senior Vice President and Head of Intrexon's Health Sector. Â "Collectively, this will assemble the most advanced set of technologies to empower the strongest adoptive cell therapy pipeline that can drive innovation through multiple horizons and patient populations."
Cooper, Hackett and colleagues developed a non-viral DNA plasmid-based gene transfer system to modify T cells by creating a CAR that recognizes and binds to a specific cell surface protein on targeted malignant cells. The testing of this system at MD Anderson in humans paves the way for the rapid design and implementation of modified T cells that can be infused into patients with many types of malignancies.
Work continues in conjunction with MD Anderson's Moon Shots Program, an ambitious initiative to accelerate the conversion of scientific discoveries into clinical advances and significantly reduce cancer deaths, first targeting eight types of cancer. Cooper leads the Applied Cellular Therapeutics platform for the moon shots, providing expertise and new cellular therapy capabilities for both blood and solid tumor cancers. Clinical trials using non-viral adoptive cellular therapies are either under way or planned for specific moon shot cancers.
The shared infrastructure between MD Anderson, Intrexon and ZIOPHARM enables two approaches to deliver these commercially viable T cells to the bedside.  The first develops a point-of-care approach with rapid assembly and infusion of autologous T cells.  The second arises from the universal donor platform to infuse off-the-shelf T cells using innovative activation and targeting gene programs that precisely recognize and systemically combat malignancies. The collaboration will advance these platforms in parallel with the most effective CAR-T products tested at MD Anderson graduating to multicenter trials.
"The promise of controlled, cell-based immuno-oncology therapy is that we can achieve dramatic, long duration anti-cancer results while keeping patients out of intensive care during treatment. As importantly, we can reproduce these results in a globally scalable and economically viable way," remarked Jonathan Lewis, M.D., Ph.D., Chief Executive Officer of ZIOPHARM Oncology. "The MD Anderson Cancer Center has long been a leader in cancer therapy, in terms of innovation, patient care, and the highest quality research. As part of our commitment to this important partnership and the acceleration of translational medicine, ZIOPHARM will build a base of operations in Houston to join and collaborate with the academic and medical community around this world-class institution."
"The human application of T cell therapies provides cancer patients with new hope, and the alignment of MD Anderson's immunotherapy and translational programs with Intrexon and ZIOPHARM will help make that hope a reality," Cooper said. "These two interconnected companies have first-in-class genetic tools and systems to reprogram cells and the management and regulatory expertise to undertake development of potent and focused cell-based immunotherapies."
Under the terms of the agreement, MD Anderson shall receive consideration of $100 million; $50 million from each Intrexon and ZIOPHARM, payable in shares of their respective common stock, as well as a commitment of $15 to $20 million annually over three years for researching and developing the technologies.  The parties will enter into additional collaboration and technology transfer agreements to accelerate technology and clinical development. Further details on the terms of the transaction will be available within the current reports on Form 8-K filed today by Intrexon and ZIOPHARM.
About Intrexon Corporation
Intrexon Corporation (NYSE: XON) is a leader in synthetic biology focused on collaborating with companies in Health, Food, Energy, Environment, and Consumer Sectors to create biologically-based products that improve the quality of life and the health of the planet. Through the company's proprietary UltraVector® platform and suite of technologies, Intrexon provides its partners with industrial-scale design and development of complex biological systems. The UltraVector® platform delivers unprecedented control over the quality, function, and performance of living cells. We call our synthetic biology approach and integrated technologies Better DNA®, and we invite you to discover more at www.dna.com.
About ZIOPHARM Oncology, Inc.
ZIOPHARM Oncology is a Boston, Massachusetts-based biotechnology company employing novel gene expression and control technology to deliver DNA for the treatment of cancer. ZIOPHARM's technology platform employs Intrexon Corporation's RheoSwitch Therapeutic System^® technology to turn on and off, and precisely modulate, gene expression at the cancer site in order to improve the therapeutic index. This technology is currently being evaluated in Phase 2 clinical studies of the immune system cytokine interleukin-12 for the treatment of breast cancer and advanced melanoma. The Company's synthetic immuno-oncology programs in collaboration with Intrexon also include chimeric antigen receptor T cell (CAR-T) approaches.
About MD Anderson
The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. It is one of only 41 comprehensive cancer centers designated by the National Cancer Institute (NCI). For the past 25 years, MD Anderson has ranked as one of the nation's top two cancer centers in U.S. News & World Report's annual "Best Hospitals" survey. It receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).
Trademarks
Intrexon, UltraVector, RheoSwitch Therapeutic System, RheoSwitch, RTS, and Better DNA are trademarks of Intrexon and/or its affiliates. Other names may be trademarks of their respective owners.
Forward-Looking Safe Harbor Statement:
This press release contains certain forward-looking information about ZIOPHARM Oncology, Inc. and Intrexon Corporation that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)," "feel(s)," "believe(s)," "will," "may," "anticipate(s)" and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding our ability to successfully develop and commercialize our therapeutic products; our ability to expand our long-term business opportunities; our future presentations at industry meetings; financial projections and estimates and their underlying assumptions; and future performance. All of such statements include certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of the company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include, but are not limited to: whether   any of our other therapeutic discovery and development efforts will advance further in  pre-clinical research or in the clinical trials process and whether and when, if at all, they will receive final approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies and for which indications; whether any other therapeutic products we develop will be successfully marketed if approved; our ability to achieve the results contemplated by our collaboration agreements; the strength and enforceability of our intellectual property rights; competition from other pharmaceutical and biotechnology companies; the development of, and our ability to take advantage of, the market for our therapeutic products; our ability to raise additional capital to fund our operations on terms acceptable to us; general economic conditions; and the other risk factors contained in our periodic and interim SEC reports filed from time to time with the Securities and Exchange Commission, including but not limited to, our Annual Reports on Form 10-K for the fiscal year ended December 31, 2013 and our Quarterly Reports on Form 10-Q for the quarter ended September 30, 2014. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.
Exclusive Licensing Agreement for CAR T Cell, TCR, NK Cell Programs and Associated Technologies for the Development of Non-Viral Adoptive Cellular Therapies
Combined Technologies to Leapfrog Clinical Pipeline of Next Generation Therapies Using Synthetic and Personalized Immunology
GERMANTOWN, Md., BOSTON, and HOUSTON, Jan. 13, 2015 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology and its oncology partner, ZIOPHARM Oncology (NASDAQ: ZIOP), today announced a broad exclusive licensing agreement with The University of Texas MD Anderson Cancer Center, including an exclusive sublicensing agreement through MD Anderson for intellectual property developed at the University of Minnesota for the development of non-viral adoptive cellular cancer immunotherapies.
The licensed technologies arise from the laboratory of Laurence Cooper, M.D., Ph.D., professor of pediatrics at MD Anderson and Perry Hackett, Ph.D., professor within the College of Biological Sciences at Minnesota.  The Cooper and Hackett laboratories have pioneered the design and clinical investigation of novel chimeric antigen receptor (CAR) T cell therapies using non-viral gene integration platforms. MD Anderson has built on this technology to deliver patient-derived T cells, as well as innovative approaches to generating products for universal off-the-shelf applications.  When combined with Intrexon's technology suite and ZIOPHARM's clinically tested RheoSwitch Therapeutic System® interleukin-12 modules, the resulting proprietary methods and technologies may help realize the promise of genetically modified CAR T cells by tightly controlling cell expansion and activation in the body, minimizing off-target effects and toxicity while maximizing therapeutic efficacy.
"Genetically engineering our patients' immune-system T cells to efficiently attack and destroy cancer cells represents one of the most exciting approaches with curative potential in oncology today," MD Anderson President Ron DePinho, M.D., said. "We believe coupling MD Anderson's unique CAR T cell approach with the powerful technologies of ZIOPHARM and Intrexon will allow us to build T cells that hit cancer harder, with greater precision, under tighter control and with potentially fewer side effects for patients. This agreement ranks as one of MD Anderson's most substantial collaborations and will provide significant resources to fuel its mission of Making Cancer History®."
"We are proud to see Perry Hackett's discovery and development work on Sleeping Beauty, a non-viral DNA plasmid-based gene transfer system, in conjunction with Dr. Cooper's expertise in immunotherapies, provide this breakthrough in oncology" said Brian Hermann, Vice President of Research at the University of Minnesota.
Employing novel cell engineering techniques and multigenic gene programs, the collaboration will implement next-generation non-viral adoptive cellular therapies based on designer cytokines and CARs under control of RheoSwitch® technology targeting both hematologic and solid tumor malignancies. The synergy between the platforms will be leveraged to accelerate a promising synthetic immunology pipeline, with up to five CARs expected to enter the clinic in 2015 and off-the-shelf programs initiating in 2016.
"It is a shared vision to maximize the speed and breadth of multigenic innovation for patients through the use of nimble, non-viral DNA cell manufacturing strategies that can further overcome viral packaging constraints and economic limitations," stated Gregory Frost, Ph.D., Senior Vice President and Head of Intrexon's Health Sector. Â "Collectively, this will assemble the most advanced set of technologies to empower the strongest adoptive cell therapy pipeline that can drive innovation through multiple horizons and patient populations."
Cooper, Hackett and colleagues developed a non-viral DNA plasmid-based gene transfer system to modify T cells by creating a CAR that recognizes and binds to a specific cell surface protein on targeted malignant cells. The testing of this system at MD Anderson in humans paves the way for the rapid design and implementation of modified T cells that can be infused into patients with many types of malignancies.
Work continues in conjunction with MD Anderson's Moon Shots Program, an ambitious initiative to accelerate the conversion of scientific discoveries into clinical advances and significantly reduce cancer deaths, first targeting eight types of cancer. Cooper leads the Applied Cellular Therapeutics platform for the moon shots, providing expertise and new cellular therapy capabilities for both blood and solid tumor cancers. Clinical trials using non-viral adoptive cellular therapies are either under way or planned for specific moon shot cancers.
The shared infrastructure between MD Anderson, Intrexon and ZIOPHARM enables two approaches to deliver these commercially viable T cells to the bedside.  The first develops a point-of-care approach with rapid assembly and infusion of autologous T cells.  The second arises from the universal donor platform to infuse off-the-shelf T cells using innovative activation and targeting gene programs that precisely recognize and systemically combat malignancies. The collaboration will advance these platforms in parallel with the most effective CAR-T products tested at MD Anderson graduating to multicenter trials.
"The promise of controlled, cell-based immuno-oncology therapy is that we can achieve dramatic, long duration anti-cancer results while keeping patients out of intensive care during treatment. As importantly, we can reproduce these results in a globally scalable and economically viable way," remarked Jonathan Lewis, M.D., Ph.D., Chief Executive Officer of ZIOPHARM Oncology. "The MD Anderson Cancer Center has long been a leader in cancer therapy, in terms of innovation, patient care, and the highest quality research. As part of our commitment to this important partnership and the acceleration of translational medicine, ZIOPHARM will build a base of operations in Houston to join and collaborate with the academic and medical community around this world-class institution."
"The human application of T cell therapies provides cancer patients with new hope, and the alignment of MD Anderson's immunotherapy and translational programs with Intrexon and ZIOPHARM will help make that hope a reality," Cooper said. "These two interconnected companies have first-in-class genetic tools and systems to reprogram cells and the management and regulatory expertise to undertake development of potent and focused cell-based immunotherapies."
Under the terms of the agreement, MD Anderson shall receive consideration of $100 million; $50 million from each Intrexon and ZIOPHARM, payable in shares of their respective common stock, as well as a commitment of $15 to $20 million annually over three years for researching and developing the technologies.  The parties will enter into additional collaboration and technology transfer agreements to accelerate technology and clinical development. Further details on the terms of the transaction will be available within the current reports on Form 8-K filed today by Intrexon and ZIOPHARM.
About Intrexon Corporation
Intrexon Corporation (NYSE: XON) is a leader in synthetic biology focused on collaborating with companies in Health, Food, Energy, Environment, and Consumer Sectors to create biologically-based products that improve the quality of life and the health of the planet. Through the company's proprietary UltraVector® platform and suite of technologies, Intrexon provides its partners with industrial-scale design and development of complex biological systems. The UltraVector® platform delivers unprecedented control over the quality, function, and performance of living cells. We call our synthetic biology approach and integrated technologies Better DNA®, and we invite you to discover more at www.dna.com.
About ZIOPHARM Oncology, Inc.
ZIOPHARM Oncology is a Boston, Massachusetts-based biotechnology company employing novel gene expression and control technology to deliver DNA for the treatment of cancer. ZIOPHARM's technology platform employs Intrexon Corporation's RheoSwitch Therapeutic System^® technology to turn on and off, and precisely modulate, gene expression at the cancer site in order to improve the therapeutic index. This technology is currently being evaluated in Phase 2 clinical studies of the immune system cytokine interleukin-12 for the treatment of breast cancer and advanced melanoma. The Company's synthetic immuno-oncology programs in collaboration with Intrexon also include chimeric antigen receptor T cell (CAR-T) approaches.
About MD Anderson
The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. It is one of only 41 comprehensive cancer centers designated by the National Cancer Institute (NCI). For the past 25 years, MD Anderson has ranked as one of the nation's top two cancer centers in U.S. News & World Report's annual "Best Hospitals" survey. It receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).
Trademarks
Intrexon, UltraVector, RheoSwitch Therapeutic System, RheoSwitch, RTS, and Better DNA are trademarks of Intrexon and/or its affiliates. Other names may be trademarks of their respective owners.
Forward-Looking Safe Harbor Statement:
This press release contains certain forward-looking information about ZIOPHARM Oncology, Inc. and Intrexon Corporation that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)," "feel(s)," "believe(s)," "will," "may," "anticipate(s)" and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding our ability to successfully develop and commercialize our therapeutic products; our ability to expand our long-term business opportunities; our future presentations at industry meetings; financial projections and estimates and their underlying assumptions; and future performance. All of such statements include certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of the company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include, but are not limited to: whether   any of our other therapeutic discovery and development efforts will advance further in  pre-clinical research or in the clinical trials process and whether and when, if at all, they will receive final approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies and for which indications; whether any other therapeutic products we develop will be successfully marketed if approved; our ability to achieve the results contemplated by our collaboration agreements; the strength and enforceability of our intellectual property rights; competition from other pharmaceutical and biotechnology companies; the development of, and our ability to take advantage of, the market for our therapeutic products; our ability to raise additional capital to fund our operations on terms acceptable to us; general economic conditions; and the other risk factors contained in our periodic and interim SEC reports filed from time to time with the Securities and Exchange Commission, including but not limited to, our Annual Reports on Form 10-K for the fiscal year ended December 31, 2013 and our Quarterly Reports on Form 10-Q for the quarter ended September 30, 2014. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.
Today was the response I was looking for. All the news was good. Future demand for ships that can transport NG may out strip the supply of current fleet & ships already ordered to be built.
I was hoping to see some positive movement from Investors Day today. The news seemed upbeat but I guess the market in general is bearish on energy right now.
Going after the 52 week low I see. Came close today. Hopefully you can get it on a quick dip, then back up to the 20's. I think if we start to export NG next year, this could really move
New investor here, just bought into glog today @ $16.10
Its from 11/20/2014
Link to full article -
http://www.bloomberg.com/news/2014--20/natural-gas-futures-gain-after-bigger-than-forecast-supply-drop.html
That would be great! I'm hoping upper $18's again.
From Bloomberg -
Next Week
Early pipeline data indicates that the stockpile decline will jump to 150 billion cubic feet in next week’s report, given the blast of arctic air sweeping most of the lower 48 states, said Teri Viswanath, director of commodities strategy at BNP Paribas SA in New York. The five-year average drop for the seven days ending Nov. 21 is 6 billion.
“The combination of the current withdrawals under way and that cold outlook in December is enough to keep prices moving higher,” she said.
Forecasts turned colder for next week as below-normal temperatures are expected to blanket a region from the Great Plains to Florida, said MDA Weather Services in Gaithersburg, Maryland. The Midwest will see the strongest intensity of the polar air mass descending from Canada. Unusually low readings will linger across the northern tier of states from Nov. 30 through Dec. 4.
Chicago’s low today may be 14 degrees Fahrenheit (minus 10 Celsius), 18 below normal, according to AccuWeather Inc. in State College, Pennsylvania. The reading in Dallas on Nov. 28 will drop to 31, 12 lower than average. About 49 percent of U.S. households use gas for heating.
To contact the reporter on this story: Naureen S. Malik in New York at nmalik28@bloomberg.net
Sorry, wrong link. Here's the link for XON
http://www.investorvillage.com/smbd.asp?mb=17828
I've been following them for a while. I invested in a company called Ziopharm that Intrexon is a major investor in. I followed XON when they went public and bought into them about a year ago. It's been a bumpy ride but the future looks bright.
Earnings for XON is tomorrow after the market closes. The link below is a great board for XON
http://www.investorvillage.com/smbd.asp?mb=16353
I don't post there as you have to join to post but there are great people there that share a great deal of information. One poster in particular worth reading is RobCos.
ZIOP partner XON on CNBC today. Very bullish comments.
http://finance.yahoo.com/video/herb-39-seeing-green-xon-173000000.html
Herb Greenberg bullish on XON!!!
http://finance.yahoo.com/video/herb-39-seeing-green-xon-173000000.html
ZIOPHARM Reports Second-Quarter 2014 Financial Results and Reviews Recent Activities
ZIOPHARM Oncology, Inc.
4 minutes ago
GlobeNewswire
BOSTON, Aug. 7, 2014 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (ZIOP) today announced financial results for the second quarter ended June 30, 2014, and provided an update on the company's product development activities.
"ZIOPHARM, together with our channel partner Intrexon Corporation, continues to advance a portfolio of immuno-oncology programs, with the goal of enabling a paradigm shift in cancer treatment," said Jonathan Lewis, M.D., Ph.D., chief executive officer of ZIOPHARM. "We continue to work at a rapid pace toward elucidating the enormous potential of the transformative technology driving this pipeline in a data-driven and efficient manner. We also look forward to a number of important, value-creating clinical, preclinical and strategic milestones over the balance of the year and beyond."
Recent Corporate Highlights
ZIOPHARM expanded the scope of its synthetic immuno-oncology programs in collaboration with Intrexon Corporation to include chimeric antigen receptor T-cell (CAR-T) therapy. CAR-T cells represent an emerging, high value immunological therapy that can target and destroy cancer cells displaying "personalized" fingerprints. ZIOPHARM will utilize Intrexon's RTS(R) platform that has the ability to facilitate precise regulation of one or more bioeffectors in CAR-T cells enabling physicians to control systemic effects of cell therapies with an appropriate dosing regimen of the oral activator ligand (veledimex), and eventually bring about improved safety and efficacy of these and related therapeutic strategies.
ZIOPHARM amended and restated its License and Collaboration Agreement with Solasia Pharma K.K. to grant Solasia an exclusive worldwide license to develop and commercialize darinaparsin (Zinapar(TM) or ZIO-101), in all indications for human use. Under terms of the new agreement, ZIOPHARM could receive up to $72.2 million in development and sales-based milestones and a royalty on net sales of darinaparsin. Solasia will be solely responsible for all costs related to the development, manufacturing and commercialization of darinaparsin.
Second-Quarter 2014 Financial Results
Net loss for the second quarter of 2014 was $5.6 million, or $(0.06) per share, compared to a net loss of $18.7 million, or $(0.22) per share, for the second quarter of 2013. Included in the loss for the second quarter of 2014 was a non-cash gain of $5.6 million compared to a non-cash loss of $403 thousand for the second quarter of 2013. The non-cash gain is related to the change in the fair value of the company's outstanding liability-classified warrants.
Research and development expenses were $8.3 million for the second quarter of 2014 compared to $14.7 million for the second quarter of 2013. The decrease of $6.4 million in research and development expenses is primarily attributable to reduced development of our small molecule drugs and a reduction in employees and facilities resulting from the company's restructuring put into effect during the second quarter of 2013.
General and administrative expenses were $3.0 million for the second quarter of 2014 compared to $3.7 million for the second quarter of 2013.
The Company ended the second quarter with cash and cash equivalents of approximately $53.0 million and expects its existing cash resources to support operations into the third quarter of 2015.
About ZIOPHARM Oncology, Inc.:
ZIOPHARM Oncology is a Boston, Massachusetts-based biotechnology company employing novel gene expression and control technology to deliver DNA for the treatment of cancer. ZIOPHARM's technology platform employs Intrexon Corporation's RheoSwitch Therapeutic System(R) technology to turn on and off, and precisely modulate, gene expression at the cancer site in order to improve the therapeutic index. This technology is currently being evaluated in Phase 2 clinical studies of the immune system cytokine interleukin-12 for the treatment of breast cancer and advanced melanoma. The Company's synthetic immuno-oncology programs in collaboration with Intrexon also include chimeric antigen receptor T-cell (CAR-T) approaches.
Good news out -
ZIOPHARM Oncology and Solasia Pharma Announce Global License and Collaboration Agreement for Darinaparsin
ZIOPHARM Oncology, Inc.
1 hour ago
BOSTON and TOKYO, July 31, 2014 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. ("ZIOPHARM") (ZIOP), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, and Solasia Pharma K.K. ("Solasia"), a developer of oncology pharmaceuticals in-licensed for commercialization in major markets throughout the world, announced today an amendment and restatement of their License and Collaboration Agreement for darinaparsin (Zinapar(TM) or ZIO-101) and related organoarsenic molecules.
Under the terms of the amended and restated agreement, ZIOPHARM granted Solasia an exclusive worldwide license to develop and commercialize darinaparsin, and related organoarsenic molecules, in both intravenous and oral forms in all indications for human use. In exchange, ZIOPHARM will be eligible to receive from Solasia up to $72.2 million in development and sales-based milestones, a royalty on net sales of darinaparsin, once commercialized, and a percentage of any sublicense revenues generated by Solasia. Solasia will be responsible for all costs related to the development, manufacturing and commercialization of darinaparsin. The new agreement amends and restates a 2011 agreement between the parties under which Solasia was granted exclusive rights by ZIOPHARM to darinaparsin in the territories of Japan, China, Hong Kong, Macau, Republic of Korea, Taiwan, Singapore, Australia, New Zealand, Malaysia, Indonesia, Philippines and Thailand.
Darinaparsin is a novel mitochondrial-targeted agent (organoarsenic) being developed for the treatment of various hematologic and solid cancers. It has been granted Orphan Drug Designation in the U.S. and Europe as a treatment of peripheral T-cell lymphoma (PTCL).
"As our strategic focus has shifted exclusively toward DNA therapeutics and immuno-oncology, Solasia, with whom ZIOPHARM has had a longstanding partnership, is the natural choice to advance the development of darinaparsin on a global basis," said Jonathan Lewis, M.D., Ph.D., Chief Executive Officer of ZIOPHARM. "Through a collaboration that began in 2011, Solasia has built a meaningful scientific and clinical understanding of darinaparsin, providing a strong foundation for realizing its long-term clinical value. Further, by expanding this agreement to all global territories, there exists now an additional strong incentive for Solasia to rapidly and strategically develop this potentially important product candidate in areas of unmet medical need in oncology."
"Solasia stands to benefit greatly from the acquisition of exclusive global development and commercialization rights to darinaparsin from ZIOPHARM," said Yoshihiro Arai, President and Representative Director of Solasia Pharma K.K. "Our initial Asian clinical studies with darinaparsin in the clinical setting of PTCL have been very exciting and encouraged us to expand our longstanding partnership with ZIOPHARM in order to maximize our opportunity with the darinaparsin program throughout the world. We presently plan to start pivotal clinical trials in Asia early in 2015."
About ZIOPHARM Oncology, Inc.
ZIOPHARM Oncology is a Boston, Massachusetts-based biotechnology company employing novel gene expression and control technology to deliver DNA for the treatment of cancer. ZIOPHARM's technology platform employs Intrexon Corporation's RheoSwitch Therapeutic System(R) technology to turn on and off, and precisely modulate, gene expression at the cancer site in order to improve the therapeutic index. This technology is currently being evaluated in Phase 2 clinical studies of the immune system cytokine interleukin-12 for the treatment of breast cancer and advanced melanoma. The Company's synthetic immuno-oncology programs in collaboration with Intrexon also include chimeric antigen receptor T-cell (CAR-T) approaches.
About Solasia
Solasia Pharma K.K. (Tokyo, Japan) was formed in November 2006 to address unmet needs for important new Western oncology therapies and supportive care products throughout Asia. The company's mission is to expedite patient access to unique oncology therapies through aggressive development and specialized commercialization throughout Japan, China and other Asian countries. In May 2008, Solasia acquired Asian rights to Sancuso(R) (extended release granisetron transdermal patch) from ProStrakan Group plc. In March 2011, Solasia acquired an exclusive license from ZIOPHARM Oncology, Inc. (ZIOP) to develop and commercialize SP-02/darinaparsin, in both intravenous and oral forms, across Asia including Japan, China, Hong Kong, Macau, Republic of Korea, Taiwan, Singapore, Australia, New Zealand, Malaysia, Indonesia, Philippines and Thailand. In several studies conducted in the US and other countries, darinaparsin injection has demonstrated good safety profiles and clinical responses in lymphoma, in particular peripheral T-cell lymphoma (PTCL). Solasia is currently conducting a Phase I study of darinaparsin in PTCL in Japan and Korea. Solasia has also submitted a Clinical Trial Application (CTA) for darinaparsin to commence clinical studies in China.
VANCOUVER, July 22, 2014 /Ballard Power Systems (BLDP) has received a purchase order from New Flyer Industries for the delivery of Ballard's first next-generation FCvelocity®-HD7 fuel cell power module to a North American bus manufacturer. Delivery of the power module to New Flyer Industries is planned for later this year.
The module will be utilized in a next generation New Flyer Industries fuel cell bus that will be sent to Altoona, Pennsylvania for testing and qualification prior to being deployed into revenue service under the U.S. Federal Transit Administration (FTA) National Fuel Cell Bus Program. The project will be administered by CALSTART, a member-supported organization dedicated to clean transportation alternatives.
New Flyer Industries is the leading manufacturer of heavy-duty transit buses in North America and the industry technology leader offering the broadest product line, including drive systems powered by fuel cells, clean diesel, natural gas and electric trolley as well as energy-efficient diesel-electric hybrid vehicles.
Chris Stoddart, New Flyer Industries' Vice President, Engineering said, "Ballard's next-generation fuel cell module offers simpler integration compared to earlier generations, along with the attributes that we've come to expect from Ballard fuel cell systems - power density, durability, and best-in-class engineering support."
Ballard has a long history of working with New Flyer Industries, having powered fuel cell buses in Vancouver, Chicago and the Palm Springs region dating back to the first ever prototype fuel cell bus in 1991. More recently, Ballard and New Flyer Industries partnered on the successful operation of BC Transit's fuel cell demonstration fleet of 20 buses, which ran from 2009 to 2014 in Whistler, British Columbia, accumulating nearly 4 million kilometers (2.5 million miles) in revenue service.
Steve Karaffa, Ballard Chief Commercial Officer said, "New Flyer Industries' selection of Ballard as a technology partner for its next-generation fuel cell bus is a testament to the value that our fuel cell products provide. This order is further evidence of market interest in Ballard's reliable and durable fuel cell power modules for mass transit applications."
Ballard continues to work with U.S. industry and clean transportation advocates to stimulate the use of fuel cell technology in transit buses. Increased volumes of fuel cell-powered buses are expected to support cost and price reductions through scale economies, enabling fuel cell solutions to compete more effectively with incumbent transit technologies. The FTA is playing a key role in accelerating fuel cell bus deployments and providing greater public exposure to the safe operation of zero-emission vehicles, which is leading to broader acceptance of the technology.
Ballard's FCvelocity®-HD7 features reduced parts count as well as fewer moving parts, integrated air compressor and coolant pump along with lower parasitic load. The FCvelocity®-HD7 also features fuel cell stacks manufactured using the Company's high-volume manufacturing processes.
No one but I have followed a number of penny stocks that have used reverse splits to help get listed on nasdaq. I don't think it's always a negative move. In this case, I would view it as a positive. My investment in kblb would be the same (less shares - equal $$$ amount) but if it was on the nasdaq, it would get more attention / respect than being a penny stock. IMHO
I hope your right. I was thinking, once kblb starts to produce products using monster silk & the buzz that will create, Kim might want to get listed on the nasdaq. A reverse split would be the quickest way to meet nasdaq's minimum share price requirements.
So when will the reverse split happen? My guess is it will be 1-10 if it happens
Earnings released, looks like a good report. +.04 a share compared to an expected loss of -.06 to -.09
http://secfilings.nasdaq.com/filingFrameset.asp?FileName=0001193125%2D14%2D187697%2Etxt&FilePath=%5C2014%5C05%5C07%5C&CoName=INTREXON+CORP&FormType=8%2DK&RcvdDate=5%2F7%2F2014&pdf=
No end in sight to the selling. $16.85 today, where is the management team?
I'm thinking about buying some 1-2016 leaps. $700 calls might be a bargain if the new products are a hit.
I believe it's June 6th
HONG KONG (CNNMoney)
China is going to battle! The enemy: polluting coal plants, gas-guzzling cars and smoggy cities.
Premier Li Keqiang said Wednesday that China would "declare war on pollution," acknowledging that it was a major problem for the country.
Heavy pollution "is nature's red-light warning against the model of inefficient and blind development," Li wrote in a report he delivered at China's annual parliamentary meetings. "We must strengthen protection of the ecological environment and resolve to take forceful measures."
Li set goals to lower energy consumption, reduce emissions, shut down 50,000 coal furnaces, minimize vehicle exhaust fumes and boost alternative energy sources.
Kraig Biocraft to develop spider silk factory in Vietnam By MJ Clark January 8, 2014
LANSING, Mich. – Spider silk technology that spun its first web at the University of Wyoming is going international.
Kraig Biocraft Laboratories, which partnered with UW and the University of Notre Dame to genetically engineer silkworms to produce spider silk, expects to sign and announce a landmark spider silk production agreement with the country of Vietnam.
Spider silk has a number of unusual physical properties, including much higher tensile strength and elasticity than plain old silk. Spider-silk fibers have many current and possible biomedical applications, such as improved wound bandages and fine suture materials. The material is strong enough that it's also being considered for ligament repair or replacement. Other uses include bulletproof vests, structural fabrics and automobile airbags.
Until the development of silkworms that could create spider silk, only very small quantities of spider silk was produced artificially in laboratories. Notre Dame's Malcom Fraser Jr. worked with University of Wyoming researcher Randy Lewis, a biochemist who is one of the world's foremost authorities on spider silk, and Don Jarvis, a noted molecular geneticist who specializes in insect protein production, genetically engineered silkworms in which they incorporated specific DNA taken from spiders.
Kraig's CEO, Kim Thompson, is in Vietnam meeting with numerous government officials and corporate leaders to discuss setting up the world's first comprehensive commercial spider-silk production facilities.
The move is part of Prime Minister Nguyen Tan Dung's development of a high-tech industries platform.
http://www.wyomingbusinessreport.com/article/20140108/NEWS/140109960
9 new filings with the SEC today. Looks like the insiders are busy...
Apple CEO Tim Cook sent a year-end memo to all Apple employees this week where he says Apple is working on some big stuff for 2014.
9to5Mac was the first to get its hands on the memo.
Most of the note is a recap of what happened in 2013, but Cook does tease some future products for next year:
We have a lot to look forward to in 2014, including some big plans that we think customers are going to love. I am extremely proud to stand alongside you as we put innovation to work serving humankind’s deepest values and highest aspirations. I consider myself the luckiest person in the world for the opportunity to work at this amazing company with all of you.
So what is Cook talking about? There are a handful of rumored new projects at Apple that could launch next year.
The first is the iWatch, a wearable wrist-computer. We first learned that Apple was working on the device earlier this year and the company has since made a bunch of key hires that hint its thinking about wearable technology. The most interesting hire was the Paul Deneve, the former CEO of fashion company Yves Saint Laurent. Deneve is now working on "special projects" and reports directly to Cook. Many speculate one of those special projects is the iWatch.
Then there's the new iPhone. Many expect a brand-new design for the next iPhone. There's also a good chance it'll have a larger screen, possibly 4.7-inches.
Next is Apple's rumored television set. We've heard over and over again that Apple is trying to expand its TV product, but we have yet to see any new gadgets in the category. There's still a small chance 2014 could be the year.
Finally, there's the so-called iPad Pro, which is supposedly a large iPad with about a 13-inch screen. There's also a chance that the iPad Pro will be a hybrid device, that is part laptop and part tablet, sort of like Microsoft's Surface. Rumors on the device are sketchy at best, but there is some evidence that a new kind of iPad is coming.
Read more: http://www.businessinsider.com/tim-cook-2014-memo-2013-12#ixzz2oFXAVNup
Stationary Fuel Cell Market to Undergo Outstanding Growth by 2020
by Staff Writers
London, UK (SPX) Dec 08, 2013
The stationary fuel cell market is forecast to show massive growth, climbing from $390m in 2012 to $7.52 billion by 2020, at a Compound Annual Growth Rate (CAGR) of 44.7%, thanks to increasing interest in this technology and the help of government subsidy programs, says research and consulting firm GlobalData.
According to the company's latest report*, the use of fuel cells is expected to increase significantly in several applications. The most important of these will be Combined Heat and Power systems, vehicles, material handling equipment, Auxiliary Power Units and portable charges for consumer electronics.
Additionally, stationary fuel cell installation is expected to jump from 186.9 Mega-Watts (MW) in 2013 to 6,266 MW by 2020, due to expected decreases in costs for set up, shipment and installation.
In fact, GlobalData forecasts the cost of a stationary fuel cell system to decrease by more than 50%, from $3,000 per Kilowatt (kW) in 2013 to $1,200 per kW by 2020.
Harsha Reddy Nagatham, GlobalData's Analyst covering Alternative Energy, says: "Proton Exchange Membrane fuel cells, which can be used both for stationary and transport applications, are the most common types of fuel cell currently utilized. They are less expensive to build, when compared with other types of fuel cells, and can be designed with a wide capacity range of 1 kW to 150 kW.
"In terms of installed capacity, Molten Carbonate Fuel Cells were also significant contributors in 2011 and 2012, as these are used in large MW scale on-grid or industrial power systems."
Despite the significant growth, the stationary fuel cell market could still be hindered by high manufacturing costs, due to the use of expensive materials, and lack of supporting infrastructure.
However, the analyst concludes: "Support from governments and intra-governmental research organizations may help increase economies of scale initially, and eventually reduce the manufacturing cost in pursuit of commercializing this technology on a large scale."
That is huge, thanks gator
Apple's iPhones Are The Top 9 Selling Smartphones In Japan
BCN is a Japanese company that tracks consumer electronic device sales in Japan. It publishes data on a weekly basis and in its latest findings Apple’s iPhone 5s and 5c are in the first nine positions and 11 of the top 14.
iPhone seems to be dominating the Japanese smartphone market
In BCN’s findings for the week ending December 1 (December 8 does not seem to be posted yet) the iPhone held the following positions:
iPhone 5s: #1, 2, 3, 5, 6, 7, 9, 12, 14
iPhone 5c: #4, 8, 20, 24, 26
Softbank had #1, 3, 4, 6, 20
Au had #2, 7, 8, 12, 26
NTT DoCoMo had #5, 9, 14, 24
Note that the Sony Xperia was in #10 and #11 with ZTE in #13.
In Kantar’s latest smartphone survey ending in October it estimates that the iPhone’s Japanese market share was 61.1% on a three month rolling average but hit 76.1% in the month of October. From various months of data I have for Japan this is up from a low of 47.4% in August and from 66.2% in December 2012.
From a Bloomberg article NTT DoCoMo’s CFO, Kazuto Tsubouchi, said on November 11 “From October, the number of customers exiting has decreased quite a lot. If we can even get that down to a small minus figure that we can forecast — in sumo terms, we’ll have gotten right back into the middle of the ring.” Carrying the iPhone seems to be helping NTT DoCoMo have fewer subscriber losses than it was experiencing pre-iPhone.
Strong iPhone sales should make Japan the fastest growing region for Apple again
In analyzing Apple’s 10-K Japan was Apple’s fastest growing region at 41% and 27% year over year growth in the September quarter and fiscal 2013, respectively. It also had the highest operating margin of any region at 50.7% in fiscal 2013 with the America’s in second place at 36.4%.
Japan was the only segment to increase its operating income year over year in fiscal 2013. Its operating income increased by 16% to $6.8 billion while every other segment saw theirs decline between 3% (U.S.) to 13% (China and Retail).
If BCN’s numbers are anywhere close to being right the addition of NTT DoCoMo along with new iPhones and iPads should produce stellar results in this region for at least the December quarter.
ZIOPHARM Reports Positive Interim Results in Patients With Advanced Melanoma From Ongoing Phase 1/2 Study of Ad-RTS-IL-12
ZIOPHARM Oncology, Inc.
12 hours ago
Potent biological activity observed in injected and non-injected lesions
Findings presented at Melanoma Bridge 2013 Conference
Conference Call Scheduled for 8:00 am EST on Monday, December 9
BOSTON, Dec. 7, 2013 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (ZIOP) today announced positive interim results from its ongoing Phase 1/2 study of Ad-RTS-IL-12, a novel DNA-based therapeutic candidate that is being evaluated with the oral activator, veledimex, in patients with advanced melanoma. The results from this multicenter study were presented at Melanoma Bridge 2013 Conference at the session "Best Abstracts on News in Immunotherapy", an international conference co-sponsored by Istituto Nazionale Tumori Fondazione, Sidra Medical and Research Center, and the Society for ImmunoTherapy of Cancer that is being held in Naples, Italy.
In this study, 21 patients with unresectable, recurrent stage III/IV melanoma have been treated with intratumoral injections of Ad-RTS-IL-12 and the oral activator veledimex. The purpose of the study is to evaluate the safety and tolerability of the Ad-RTS-IL-12 and veledimex therapy, determine tumor and immune response, and select the optimal dose and schedule of veledimex for future study. To date, expression of IL-12 mRNA in study subjects' tumors was determined to be very high and tightly controlled by veledimex dose with expression ranging from a median increase of approximately 1,000 times with an oral dose of 100 mg to approximately 100,000 times with an oral dose of 160 mg. In addition, upon stopping veledimex dosing, expression of the IL-12 mRNA returned to baseline levels, demonstrating the "on" and "off" control of Intrexon Corporation's (XON) RheoSwitch Therapeutic System(R) platform. In this dose range, results to date demonstrate that Ad-RTS-IL-12 + veledimex has potent biologic activity, as measured by on-mechanism and on-target toxicity and response in injected and non-injected lesions. In addition, increased tumor infiltrating lymphocytes were observed in the tumor microenvironment at these doses, suggesting multiple favorable biologic effects of IL-12 expression. Following treatment, 11 of 16 evaluable patients have demonstrated a response of stable disease or better on a per lesion basis.
The most common severe adverse events (SAEs) were pyrexia, hypotension, mental status changes, and cytokine release syndrome. Four of seven patients with SAEs had veledimex dosing stopped during cycle 1. Three had SAEs during subsequent cycles, and stopped veledimex dosing at that time. Importantly, all SAEs were reversed after veledimex dosing was stopped, demonstrating the "on" and "off" control of veledimex on gene expression.
"Immunotherapy is a powerful and promising approach to the treatment of many cancers, including advanced melanoma," said Dr. John Nemunaitis, MD, Executive Medical Director, Mary Crowley Medical Research Center, and lead investigator of the study. "A major limitation to turning on the immune system in cancer is the many checks and balances that mask the tumor from the immune system. Delivery of interleukin-12 using the regulated gene expression system Ad-RTS-IL-12 provides us with the ability to turn on the immune system and finely control this potent anti-cancer immune response to derive clinical effect and manage tolerability. To date, this study has demonstrated immune response and encouraging activity, along with a tolerability profile that is well controlled by dose of the activator ligand veledimex. This should combine well with other emerging treatments to create a new treatment option for advanced melanoma and other cancers."
"The ability to precisely modulate gene expression at the site of the cancer represents a potential paradigm shift in cancer treatment," said Francois Lebel, M.D., Senior Vice President, Clinical Development and Medical Operations at ZIOPHARM. "We believe the evidence of safety, efficacy and control of gene expression in this study is encouraging and warrants the completion of this trial and the pursuit of a larger Phase 2 clinical trial in patients with advanced melanoma in 2014. We look forward to reporting the full results of this study at a future medical meeting and to initiating later-stage clinical testing in a larger patient population."
ZIOPHARM is developing Ad-RTS-IL-12 using Intrexon Corporation's RheoSwitch Therapeutic System(R) platform to control the expression of interleukin-12 and enable its safe and effective delivery as an anti-tumor agent. The company is advancing the Ad-RTS-IL-12 platform in melanoma, breast cancer and glioblastoma.
Conference Call Information:
ZIOPHARM management, joined by Larry Norton, M.D., Deputy Physician-in-Chief for Breast Cancer Programs, Memorial Sloan-Kettering Cancer Center, Medical Director, Breast Cancer Programs, will host a conference call and live audio webcast on Monday, December 9, 2013, at 8:00 AM ET. The call can be accessed by dialing (877) 402-8188 (U.S. and Canada) or (330) 871-4581 (international). The passcode for the conference call is 'ZIOPHARM.' To access the live audio webcast, or the subsequent archived recording, visit the "Investors - Events & Presentations" section of the ZIOPHARM website at www.ziopharm.com. The webcast will be recorded and available for replay on the Company's website for two (2) weeks.
ZIOPHARM and Intrexon Announce Presentations at the 2013 AACR-NCI-EORTC International Conference
ZIOPHARM Oncology, Inc. (ZIOP), a biopharmaceutical company focused on the discovery and development of new cancer therapies, and Intrexon Corporation (XON), a leader in synthetic biology, today announced scheduled poster presentations at the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, which is taking place October 19-23, 2013 in Boston. The conference is a joint meeting of the American Association for Cancer Research, the National Cancer Institute and the European Organisation for Research and Treatment of Cancer. The presentations will highlight studies conducted jointly between ZIOPHARM and Intrexon as part of an Exclusive Channel Collaboration to research, develop and commercialize novel in vivo DNA- and cell-based oncology therapeutics using different approaches, regulated by Intrexon's proprietary RheoSwitch Therapeutic System(R) (RTS(R)) platform.
The studies concern ZIOPHARM's lead therapeutic program, a monogenic system which enables the controlled delivery of therapeutic interleukin-12 (IL-12), in a glioma (brain tumor) model, as well as pipeline programs exploring: embedded cellular bioreactors capable of expressing three distinct immune effectors from a single RTS(R) gene switch; the use of mesenchymal stem cells for tumor targeted delivery of single or multiple regulated cancer immunotherapies; and the expression of high affinity single chain variable fragment-Fc (scFv-Fc) antibodies with target specificities based on trastuzumab (anti-Her2) and cetuximab (anti-EGFR) for gene therapy applications. ZIOPHARM expects to file multiple investigational new drug (IND) applications in 2014 and 2015 to begin exploring new targets in the clinic using technologies such as these.
The findings will be presented on Oct. 21 and 22, 2013. Specific times and locations are noted below.
Title: Pharmacodynamics and Functionality of RheoSwitch(R) Regulated Immunomodulatory Proteins, Expressed from a Multigenic Embedded Cellular Bioreactor Following Intramuscular Electroporation in Mice
Abstract #: B127
Date and Time: Monday, Oct 21, 2013 12:30 PM - 3:00 PM
Session: Poster Session B; Gene Therapies
Location: Exhibit Hall C-D
Title: The Controlled Local Expression of IL-12 as an Immunotherapeutic Treatment of Glioma Through the use of the RheoSwitch Therapeutic System(R) (RTS(R)) Platform
AACR -
The mission of the American Association for Cancer Research is to prevent and cure cancer through research, education, communication, and collaboration. Through its programs and services, the AACR fosters research in cancer and related biomedical science; accelerates the dissemination of new research findings among scientists and others dedicated to the conquest of cancer; promotes science education and training; and advances the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world.
Where will the cure for cancer come from?
The answer is research. Cancer is not a single disease, but more than 200. In the U.S. and around the world, men and women in laboratories and clinics, universities, medical centers, government, and industry are working not only to overcome this affliction that claims half a million American lives each year, but also to prevent it. More than 34,000 of them are members of the American Association for Cancer Research.
How does the AACR promote cancer research?
The AACR is the authoritative source of information about advances in the causes, diagnosis, treatment and prevention of cancer. By accelerating the growth and spread of new knowledge about cancer, the AACR is on the front lines of the quest for prevention and cure.
What does the AACR do?
The AACR is the oldest and largest scientific organization in the world focused on every aspect of high-quality, innovative cancer research. Its reputation for scientific breadth and excellence attract the premier researchers in the field. The programs and services of the AACR foster the exchange of knowledge and new ideas among scientists dedicated to cancer research, provide training opportunities for the next generation of cancer researchers, and increase public understanding of cancer.
To that end, the AACR:
Currently publishes a portfolio of highly ranked peer-reviewed journals that present leading research articles: Cancer Discovery, Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; Cancer Epidemiology, Biomarkers & Prevention; Cancer Prevention Research, and our newest journal, Cancer Immunology Research. Our scientific breadth and excellence continue to attract the premier researchers in the field, and we are proud to note that the AACR journals rank in the top 25 percent of oncology journals with regard to Impact Factor in the Journal Citation Report (2012).
Publishes Cancer Today, the authoritative resource for cancer patients, survivors, and caregivers who are seeking information and inspiration as they or their loved ones face diagnosis, treatment, and life after cancer.
Convenes topical scientific conferences and an annual meeting that draws more than 18,000 participants from the cancer research community.
Offers workshops, fellowships, and grants for early-career investigators and investigators-in-training.
Collaborates with cancer survivors, raises public awareness of the progress in and cause for hope in cancer research, and advocates for strong federal research funding.
How did the AACR begin?
AACR was founded in 1907 by a group of 11 physicians and scientists interested in research, "to further the investigation and spread the knowledge of cancer." Today, the AACR accelerates progress toward the prevention and cure of cancer by promoting research, education, communication, and collaboration.